J Cardiovasc Pharmacol. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2 - FluTrackers News and Information

Do not take medical advice from the internet. If you have any medical questions please consult your medical practitioner.

LATEST POSTS - click HERE

Check out the FAQ,Terms of Service & Disclaimers by clicking the link. Please register to be able to post. By viewing this site you are agreeing to our Terms of Service and Acknowledge our Disclaimers.

FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.

We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Announcement

Collapse

No announcement yet.

J Cardiovasc Pharmacol. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2

Collapse

X

Collapse

Posts

Latest Activity

Photos

Page of 1

Filter

Time

All Time Today Last Week Last Month

Show

All Discussions only Photos only Videos only Links only Polls only Events only

Filtered by:

Clear All

new posts

Previous template Next

tetano

Editor, Senior Moderator

Join Date: Dec 2009

Posts: 111210

Share

Tweet

#1

J Cardiovasc Pharmacol. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2

April 18, 2020, 06:42 AM

J Cardiovasc Pharmacol. 2020 Apr 13. doi: 10.1097/FJC.0000000000000840. [Epub ahead of print]
Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.

Buckley LF¹, Cheng JWM^1,², Desai A³.

Author information

Abstract

Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.

PMID:32301766DOI:10.1097/FJC.0000000000000840

Tags: None

Previous template Next

Help

Contact Us

Go to top

Powered by vBulletin® Version 5.7.5
Copyright © 2026 MH Sub I, LLC dba vBulletin. All rights reserved.

All times are GMT-5. This page was generated at 07:35 PM.

Working...

X